Allos Therapeutics, Inc.
11080 CirclePoint Road
Suite 200
Westminster
Colorado
80020
United States
Tel: 303-426-6262
Fax: 303-426-4731
Website: http://www.allos.com/
Email: corpcomm@allos.com
210 articles about Allos Therapeutics, Inc.
-
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.
-
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
Spectrum Pharmaceuticals, Inc. Completes Acquisition of Allos Therapeutics, Inc.; Effective and Swift Integration Expected to Result in Significant Synergies
9/6/2012
-
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics
9/5/2012
-
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce That Federal Trade Commission Clears Transaction; Tender Offer for Shares of Allos Common Stock to Expire at 5pm Eastern Time on September 4, 2012
8/29/2012
-
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
8/20/2012
-
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
8/6/2012
-
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
7/23/2012
-
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
7/9/2012
-
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
6/22/2012
-
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
6/8/2012
-
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
5/25/2012
-
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. Announce Extension of Previously Announced Tender Offer for Shares of Allos Therapeutics
5/10/2012
-
Allos Therapeutics, Inc. Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe
4/20/2012
-
Spectrum Pharmaceuticals, Inc. Commences Tender Offer for All Outstanding Shares of Allos Therapeutics, Inc.
4/16/2012
-
Spectrum Pharmaceuticals, Inc. Scoops Up Allos Therapeutics, Inc. in Deal Worth $206 Million as Bladder Cancer Drug Fails Phase 3
4/6/2012
-
Allos Therapeutics, Inc. (ALTH) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition By Spectrum Pharmaceuticals, Inc.
4/6/2012
-
Allos Therapeutics, Inc. Reports Fourth Quarter and Full Year 2011 Financial Results
3/7/2012
-
Allos Therapeutics, Inc. to Report Fourth Quarter and Full Year 2011 Results on March 6, 2012
2/21/2012
-
Allos Therapeutics, Inc. Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at theEuropean Medicines Evaluation Agency
1/30/2012